Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;187(3):437-438.
doi: 10.1111/bjd.21235. Epub 2022 May 27.

Mycophenolate mofetil and methotrexate efficacy in dermatomyositis

Madison Grinnell  1   2 , Emily Keyes  1   2 , DeAnna Diaz  1   2 , Thomas Vazquez  1   2 , Rui Feng  3 , Victoria P Werth  1   2
Affiliations

Mycophenolate mofetil and methotrexate efficacy in dermatomyositis

Madison Grinnell et al. Br J Dermatol. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: We have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
MMF Takers and MTX Takers CDASI Activity Scores, Inset showing first 180 days of therapy
See this image and copyright information in PMC

References

    1. Anyanwu CO, Chansky PB, Feng R, Carr K, Okawa J, Werth VP. The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy. International journal of women’s dermatology. 2017;3(4):189–94. - PMC - PubMed
    1. Anyanwu CO, Fiorentino DF, Chung L, Dzuong C, Wang Y, Okawa J, et al. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015;173(4):969–74. - PMC - PubMed
    1. Ahmed S, Chakka S, Concha J, Krain R, Feng R, Werth VP. Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis. Br J Dermatol. 2020;182(4):949–54. - PMC - PubMed

MeSH terms